The primary focus of this workshop is to teach medical professionals how to successfully incorporate stem cell treatments into their practices. Expert faculty will cover stem cell theory and clinical trial research for all aspects of regenerative medicine as well as stem cell treatment marketing.
Dr. Riordan will discuss: Allogeneic mesenchymal stem cells' mechanisms of immune modulating activities; the importance of MSC placement for clinical effect; human clinical trials demonstrating efficacy; alternative routes of MSC delivery; dose and frequency; and clinical safety of MSC.
The conference will be held from
About Neil Riordan PhD
Dr. Riordan is the founder and chairman of
Under the umbrella of MPI subsidiary Translational Biosciences, MPI and SCI are currently conducting five IRB-approved clinical trials in
Dr. Riordan is an accomplished inventor listed on more than 25 patent families, including 11 issued patents. He is credited with a number of novel discoveries in the field of cancer research since the mid-1990s when he collaborated with his father Dr.
Dr. Riordan is also the founder of Aidan Products, which provides health care professionals with quality nutraceuticals including Stem-Kine, the only nutritional supplement that is clinically proven to increase the amount of circulating stem cells in the body for an extended period of time. Stem-Kine is currently sold in 35 countries.
Dr. Riordan earned his Bachelor of Science at
About Stem Cell Institute Panama
Founded in 2007 on the principles of providing unbiased, scientifically sound treatment options; the
In partnership with Translational Biosciences, a subsidiary of Medistem Panama, SCI provides clinical services for ongoing clinical trials that are assessing safety and signs of efficacy for osteoarthritis, rheumatoid arthritis, and multiple sclerosis using allogeneic umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC), autologous stromal vascular fraction (SVF) and hU-MSC-derived mesenchymal trophic factors (MTF). In 2014, Translation Biosciences expects to expand its clinical trial portfolio to include spinal cord injury, heart disease, autism and cerebral palsy.
For more information on stem cell therapy:
Stem Cell Institute Website: http://www.cellmedicine.com
Since opening its doors in 2007,
Ciudad del Saber,
Phone: +507 306-2601
Fax: +507 306-2601
About Translational Biosciences
A subsidiary of
Translational Biosciences Web Site: http://www.translationalbiosciences.com
Read the full story at http://www.prweb.com/releases/2014/05/prweb11847056.htm
Articles featured in Life Extension Daily News are derived from a variety of news sources and are provided as a service by Life Extension. These articles, while of potential interest to readers of Life Extension Daily News, do not necessarily represent the opinions nor constitute the advice of Life Extension.